Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Thrombocytopenia 7Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1Lung Neoplasms 1Glioblastoma 1Chemotherapy-induced Thrombocytopenia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Darbepoetin alfa 3Tinzaparin 2Epoetin Alfa 2Cisplatin 2sotorasib 1romiplostim 1pegfilgrastim 1continuous erythropoietin receptor activator 1Tretinoin 1Rivaroxaban 1Nadroparin 1Gemcitabine 1Fondaparinux 1Docetaxel 1Dalteparin 1Carboplatin 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × romiplostim × Classical hematology × Clear all
NCT00413283 2013-10-24

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

Phase 2 Completed
63 enrolled 15 charts
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡